India is struggling with a sharp rise in COVID-19 infections that have shaken hospitals and made them sleepy and shortness of breath.
A key question is whether a new type of risk factor for change – B.1.617 – is the cause of the world’s fastest-growing emergencies, which added to more than 330,000 cases on Friday.
Version B.1.617 has already appeared elsewhere, including in the United States, Australia, Israel and Singapore. Concerns about this have led other countries, including the United Kingdom and Canada, to introduce travel bans in India.
Here’s what we know so far.
When did it start?
Viruses change all the time and the cause of COVID-19 has already changed several thousand – some about others.
India also reported genome B.1.617 in the global database (GISAID) in October.
India’s health ministry also reported the change at the end of March, saying it appeared in 15-20% of the cases reviewed. the palace of Maharashtra. Recently, the figure was 60 percent.
The change is also available in 18 other countries starting this month, according to GISAID.
Should we be worried?
B.1.617 was classified as a World Health Organization as a “variety of interest”.
Some species found in Brazil, South Africa and the UK have been classified as “essential” because they are contagious, dangerous or reduce the effectiveness of the drug.
B.1.617 has several variables, including two well-known ones (E484Q and L452R), which make them sometimes referred to as “double mutant”.
The first similar change is similar to another (E484K or sometimes called “Eek”) observed in South Africa, Brazil, and more recently, UK genres.
“Eek” was called “adaptable” because it helps the virus pass through the immune system.
Another notable change was found in a California study to become an effective publisher.
Scientists say there is a need for more evidence to suggest whether these changes make the B-type B.1.617 more dangerous.
Are there differences that cause the rise of India?
Rakesh Mishra, director of the Hyderabad-based Center for Cellular and Molecular Biology, is one of the scientists examining type B.1.617.
So far, he says, it has been “better for distribution than any other nation”.
“Gradually it will become more common and it will change some,” he told AFP.
It is not known, however, whether the modern Indian wave is connected to this, or whether it is driven by human systems or something.
Health experts have expressed deep concern over recent religious festivals and political rallies.
However, several countries are not doing anything with B.1.617. When banned from traveling from India this week, the UK cited particularly fears of a new kind.
On Wednesday, the US also advised travel to India, saying “even travelers with the vaccine could be at risk of obtaining and distributing COVID-19 varieties”.
Is the vaccine effective?
One of the changes is the “Eek” approach, which is thought to reduce the risk of infection from viruses or vaccines, says University of Utah technical researcher Stephen Goldstein.
Mishra says that scientists are trying to use vaccines against these differences.
Nevertheless, experts say that vaccines still offer some protection, especially in extreme cases.
As more species are released when they become infected, Mishra said India should be responsible for the virus.
Another brand, B.1.618, recently hoisted red flags when it became the third most popular in India.
Goldstein commented on the UK’s success in reversing the recent emergence despite the various possible changes.
“It can be difficult, but it can happen,” he told AFP.
“I think the vaccination campaign really helped … but the closure is what helped them reduce crime and start making changes.”